Herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) gene therapy can induce apoptosis in tumor cells that are normally resistant to this type of cell death, although the cellular mechanisms by which this occurs remain to be elucidated. Human colon tumor cell lines expressing HSV-TK were treated with GCV or four other inducers of apoptosis: butyrate, camptothecin (CPT), Taxol (paclitaxel), or 7-hydroxystaurosporine (UCN-01). Over a 2-4 day treatment period with GCV or the other four drugs, protein levels of the apoptosis agonist Bak increased 1.5-to 3-fold, whereas a corresponding decrease in the levels of the apoptosis antagonist, Bcl-X L , was observed in butyrate-, CPT-, and 7-hydroxystaurosporine (UCN-01)-treated cells. GCV and paclitaxel treatments resulted in increased levels of Bcl-X L . In two-drug combinations with GCV plus one of the four other drugs, increased tumor cell killing was found with GCV plus UCN-01 or with some GCV/butyrate combinations; the other two tested combinations were largely antagonistic. The GCV/UCN-01 and GCV/butyrate combinations resulted in increased Bak and decreased Bcl-X L protein levels, while the GCV/CPT and GCV/paclitaxel combinations resulted in increased levels of both proteins. The results highlight the potential for new combination therapies of HSV-TK/GCV and chemotherapeutic drugs that result in increased tumor cell apoptosis for future treatments of colon cancer.
D elivery and expression of herpes simplex virus thymidine kinase (HSV-TK) in combination with ganciclovir (GCV) has shown great clinical promise as a gene therapy of different cancers. [1] [2] [3] [4] Many studies in animal models have demonstrated a dramatic antitumoral immune response to HSV-TK-expressing tumors and distant non-TK-expressing tumors after GCV treatments that results in complete eradication of the tumor. 1, [5] [6] [7] [8] [9] [10] In results from phase I/II clinical trials, however, only a small percentage of patients have had complete tumor regressions after HSV-TK/GCV treatments. [1] [2] [3] For solid tumor therapies, the majority of patients have had only partial or minimal responses to the therapy, and it is likely that this is due to a combination of gene delivery and targeting issues, poor tumor bystander effect sensitivities, and weak antitumoral immune responses. [1] [2] [3] One potential way to improve the in vivo effect would be to coadminister chemotherapeutic agents that work with HSV-TK/GCV to increase initial tumor cell killing in an attempt to potentiate the antitumoral immune response.
It has been well established in many cell systems that GCV induces apoptosis in HSV-TK-expressing tumor cell lines. [11] [12] [13] [14] GCV is a prodrug that must be phosphorylated by HSV-TK and cellular kinases to the toxic triphosphate form, GCVTP, which acts as an inhibitor of DNA replication and DNA polymerase ␦. 12, 15, 16 It has been concluded that the cumulative incorporation of GCVTP into DNA and the resulting persistent damage are the primary pharmacological effects of GCV administration. 11, 12, 17 Many subsequent effects on the cellular response to this GCV damage and induction of cell death pathways remain to be elucidated. Recently, GCV has been reported to induce S-and G 2 -M phase cell cycle arrest in HSV-TK-expressing cells, 11, 12, 17 and these changes were associated with modulation of Cdc2/cyclin B activities 17 and increased levels of cyclin B1. 11 Although the effects of GCV on cell cycle arrest are being clarified, the factors that positively and negatively regulate apoptosis after GCVTP inhibition of DNA replication in the HSV-TK-expressing or bystander cells are not known.
Changes in the levels of two Bcl-2 family members, Bak and Bcl-X L , have been specifically implicated both in the development of colorectal cancer and in the mechanism of cell death induced by pro-apoptotic agents. In a study of a series of different colon tissues representative of the progression from normal to adenocarcinoma, expression of the pro-apoptotic protein, Bak, was shown to be down-regulated, whereas expression of the anti-apoptotic protein, Bcl-X L , was shown to increase as tissues progressed toward adenocarcinoma. 18 The levels of Bcl-2 and other family members did not correlate with progression. Previous studies have demonstrated that the cellular level of Bcl-X L decreases or can prevent or delay the apoptosis induced by camptothecin (CPT), 19 sodium butyrate, 20 -22 Taxol (paclitaxel), 19 and many other drugs. 19, 23 Conversely, it has been shown that butyrate 24 or Taxol 25 treatments can lead to increases in the level of the pro-apoptotic Bak protein and to increased induction of apoptosis. In regards to their role in colon tumor cells, Bak and Bcl-X L collectively appear to be the primary Bcl-2 family members involved in the regulation of apoptosis in colon tumor cells. 18, 21, 24 The effect of GCV treatment on the levels of Bcl-2 family members in HSV-TK-expressing colon tumor cells has not been investigated previously. Previous studies have demonstrated that overexpression of Bcl-2 in murine fibroblasts inhibited GCV-mediated bystander killing.
14 and in ovarian tumor cells expressing HSV-TK, it was shown that levels of the pro-apoptotic protein Bax increased in response to GCV. 26 For our current study, the protein levels of Bak and Bcl-X L were determined in several HSV-TK-expressing colon tumor cell lines treated with GCV and compared with cells treated with four mechanistically distinct inducers of apoptosis: sodium butyrate (a histone deacetylase inhibitor), CPT (a topoisomerase I inhibitor), Taxol (a microtubule spindle inhibitor) or UCN-01 (a protein kinase C class inhibitor). Cell viability assays, comparative Western blot analyses of Bak and Bcl-X L levels, and nuclear 4Ј,6Ј-diamidine-2Ј-phenylindoledihydrochloride (DAPI) staining were used to monitor the cellular and apoptotic effects of single-drug and two-drug combinations. The results indicate that a combination of GCV with UCN-01 leads to increased apoptosis and tumor cell killing, which can be correlated with increased protein levels of Bak and decreased levels of Bcl-X L . The GCV plus butyrate combination yielded mixed results, whereas the Taxol and CPT combinations with GCV were antagonistic. Cumulatively, we demonstrate that the induction of apoptosis and rate of cell death can be modulated with two-drug combinations in HSV-TKexpressing cells. These types of drug combinations could prove to be clinically beneficial in future gene therapies for cancer.
MATERIALS AND METHODS

Materials
DAPI, sodium butyrate, Taxol, and CPT were obtained from Sigma (St. Louis, Mo). UCN-01 was obtained from the Developmental Therapeutics Program of the National Cancer Institute (Bethesda, Md). Rabbit polyclonal antibody (Ab) to Bcl-X L was provided by Transduction Laboratories (Lexington KY), Bak rabbit polyclonal Ab was obtained from Santa Cruz Biotechnology (Santa Cruz, Calif), and horseradish peroxidase-conjugated goat anti-rabbit secondary Ab was obtained from Bio-Rad (Hercules, Calif). Nitrocellulose blotting membranes were provided by Schleicher and Schuell (Keene, NH).
Colon tumor cell lines and HSV-TK-expressing cell lines
All human colon tumor cell lines (SW620, SW480, HCT-8, HT-29, and HCT-116) and their derivatives were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. All cell lines were obtained from the American Type Culture Collection (Manassas, Va). The HSV-TK-expressing cell lines HCT-116.TK, HT-29.TK, HCT-8.TK, and PA317.TK were generated using a bicistronic HSV-TK ϩ Moloney murine leukemia virus vector, pLTKEN, as described previously. 27 The SW480.TK and SW620.TK cell lines were generated using this same vector after G418 selection (0. 
DAPI staining of apoptotic cells
HSV-TK-expressing tumor cells or PA317.TK cells (1 ϫ 10 5 ) were plated in 4-well chamber slides (Nalge Nunc, Naperville, Ill) in media plus or minus 25 M GCV. HCT-116.TK and PA317.TK cells were incubated with GCV for 48 hours, whereas the SW480.TK, SW620.TK, and HT-29.TK cells were incubated for 60 hours. At the endpoint, the cells were washed with phosphate-buffered saline and stained with 1 g/mL DAPI in 100% methanol at 37°C for 10 minutes. 28, 29 After rinsing, the stained cells were visualized with a Zeiss fluorescent microscope (Thornwood, NY) at ϫ40 magnification with a DAPI-specific filter.
Western blot analysis of Bcl-X L and Bak in drugtreated cells HSV-TK-expressing cells (3-4 ϫ 10 6 in T-25 flasks) were treated with 25 M GCV for various times (0 -72 hours); HCT-116 cells were treated with either 1 M CPT, 3 mM sodium butyrate, 25 nM Taxol, or 1 M UCN-01 for 0 -48 hours. At each indicated timepoint, cells were removed by trypsin, pelleted and rinsed, counted, and resuspended in 0.1 mL of 0.25ϫ electrophoresis sample buffer (4 M urea, 20 mM dithiothreitol, 100 mM tris(hydroxymethyl)aminomethane (pH 8.0), 4% (wt/vol) sodium dodecyl sulfate (SDS), and bromophenol blue). Only adherent cells were analyzed; floating cells in the media were discarded. These samples were then boiled for 5 minutes and passed two times through a 26-gauge needle. Protein concentrations were determined for each sample (BioRad), and 100 g protein/sample was separated on 14% SDS-polyacrylamide gels. Protein was transferred to a nitrocellulose membrane and incubated with Abs directed toward either Bcl-X L or Bak for 1 hour. Due to concerns regarding normalization of all of the different two-drug combinations and their unknown effects, blotting of standard internal control cytoskeletal or metabolic enzymes was not done. Instead, each gel or blot was stained with Coomassie blue to verify that equal amounts of sample protein had been loaded per well. A secondary anti-rabbit Ab conjugated with horseradish peroxidase was used with enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia, Piscataway, NJ) for chemiluminescence detection on film.
Caspase 3 assay
Caspase 3-like activity was assayed in drug-treated cells using an Apo-Alert CPP32/Caspase 3 Colorimetric Assay kit according to the manufacturer's instructions (Clontech Laboratories, Palo Alto, Calif) with the peptide substrate, DEVD-pNA. Samples were quantitated using a Shimadzu ultraviolet/visible spectrophotometer (Shimadzu, Columbia, Md) set at 405 nm.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assays and clonal dilution assays .TK cells were seeded in 96-well plates in 0.1 mL of media (20,000 cells/well). On the following day, a dose range of drug alone or in combination was added in a total of 0.1 mL of media. After 2 days, MTT (50 g/well) was added for 1.5 hours, followed by dimethylsulfoxide solubilization of the cells, and absorbance readings at 540 nm 30 For clonal dilution assays, HCT-116.TK or SW620.TK cells were seeded in 24-well plates at 70% confluency (2 ϫ 10 5 cells/well) in 1 mL of media. On the following day, drugs singly or in combination with GCV were added to each cell line in triplicate. After 24 hours, medium was removed from each well. Cells were rinsed twice in fresh media, treated with 0.2 mL trypsin/ethylenediaminetetraacetic acid, and media was added to 1 mL per well. Each well of cells was then sequentially diluted from 1/10 to 1/10,000 in 1 mL of fresh media on a separate 24-well plate. After 7 days, surviving cell colonies were fixed in 100% methanol, stained with 0.1% methylene blue, and counted. A colony was defined as consisting of Ն10 cells.
RESULTS
Detection of apoptosis in HSV-TK-expressing cell lines
The morphological characteristics of apoptosis include cell shrinkage, maintenance of an intact membrane, nuclear condensation, DNA fragmentation, and the presence of apoptotic vesicles. 31, 32 It has been well established using many late-stage apoptosis assays that GCV treatment induces apoptosis in HSV-TK-expressing cell lines. [11] [12] [13] [14] Apoptosis induced by treatment with GCV for 48 -72 hours was evaluated in five HSV-TKexpressing cell lines. Nuclear condensation and partitioning associated with apoptotic cell death was visualized by staining of nuclei with DAPI. 28, 29 As shown in Figure 1 , DAPI staining of GCV-treated PA317.TK cells revealed nuclear condensation and partitioning characteristic of apoptosis, which is consistent with a previous report.
14 Similar nuclear effects were observed in the four colon tumor cell lines treated with GCV (HCT-116.TK, SW620.TK, SW480.TK, and HT-29.TK). These effects were not observed in untreated cells or in GCVtreated non-HSV-TK-expressing parental cells. Similarly, terminal deoxynucleotidyltransferase fluoresceinlabeled deoxyuridine triphosphate nick end labeling assays performed on GCV-treated HSV-TK-expressing cells indicated fluorescent end-labeling of fragmented DNA (data not shown).
Activation of the executioner protease, caspase 3 (or CPP32), is common to many apoptotic pathways, and its target proteins are responsible for producing the morphological features associated with the late stages of apoptosis. 33, 34 A colorimetric peptide substrate assay 35 for caspase 3 was done with lysates from HCT-116.TK cells incubated in the absence or presence of 25 M GCV for 24 hours. Because this substrate can be used by proteases that are similar to caspase 3, this activity is referred to as a caspase 3-like activity. As shown in Figure 2 , lysates from the GCV-treated cells demonstrated a 5.8-fold induction of caspase 3-like activity. Addition of 50 M DVED-fmk, a competitive inhibitor of caspase 3, decreased activity back to untreated control levels. For comparison, the results of caspase 3-like activation in HCT-116 cells treated with CPT and in PA317.TK packaging cells treated with GCV are also presented (Fig 2) . The DAPI staining and caspase 3 assays confirmed that GCV treatment leads to induction of apoptosis in these HSV-TK-expressing colon tumor cell lines.
Changes in protein levels of Bak and Bcl-X L in GCVtreated HSV-TK-expressing colon tumor cell lines Most previous studies on GCV-induced apoptosis have focused on analysis of the latter stages of the process, and little is known about the cellular mediators involved. Because changes in Bak and Bcl-X L levels have been implicated in the progression and treatment of colorectal carcinoma, 18 the effects on these protein levels in five HSV-TK-expressing colon tumor cell lines treated with GCV were determined. For each cell line, a time course of relative Bak protein levels was done in the HCT-116.TK, HT-29.TK, HCT-8.TK, SW620.TK, and SW480.TK cell lines. Cells were treated with or without 25 M GCV for various times (24 -90 hours), and only adherent cells were processed for Western blot analysis as described in Materials and Methods. As shown in Figure 3A , Bak expression increased in four of the five cell lines treated with GCV, the exception being the SW480.TK cells. Densitometric measurements of these bands indicated a 1.5-to 3-fold increase in Bak protein levels that persisted throughout the treatment. A previous report demonstrated that Bak levels can increase with cell density in cultured cell lines, 36 and differences in Bak levels between untreated controls for the first and HCT-116 cells (Ⅺ) were treated in the absence or presence of 1 M CPT for 48 hours. Cell lysates were prepared, and caspase 3 assays were performed using a colorimetric Clontech Apo-Alert CPP32/Caspase 3 kit according to the manufacturer's instructions. Relative caspase activity was determined by 405 nm optical density readings of the cleaved DEVD-pNA substrate. last timepoints were also observed in our cell lines. The same GCV-treated samples were analyzed for changes in the protein levels of the anti-apoptotic protein, Bcl-X L , by Western blot analysis (Fig 3B) . As observed with Bak, Bcl-X L protein levels increased 2-to 3-fold in four of the five GCV-treated cell lines, with the exception again being the SW480.TK cells. When early time courses of these changes were done with HCT-116.TK cells (6 -24 hours), Western blot analysis indicated that Bak and Bcl-X L protein levels increased 2-to 3-fold as early as 14 hours in comparison with the control cell lysates (data not shown). Analysis of Bcl-2 and Bax levels in HT-29.TK and HCT-116.TK cells indicated no differences in their expression levels on GCV treatment (data not shown); thus, they were not further analyzed in the other cell lines. Although the overall changes in Bak and Bcl-X L protein levels were modest, one proposed mechanism for induction of apoptosis is the upset in the dimerization ratio of pro-apoptotic and anti-apoptotic Bcl-2 protein family members. 37 Thus, small changes in Bak levels relative to Bcl-X L can have important proapoptotic consequences.
Changes in protein levels of Bak and Bcl-X L in HCT-116 cells treated with apoptosis-inducing drugs Because GCV treatment led to increases in the protein levels of both Bak and Bcl-X L , HCT-116 colon tumor cells were treated with other apoptosis-inducing agents for different timepoints (3 mM sodium butyrate, 1 M CPT, 25 M GCV, 25 nM Taxol, or 1 M UCN-01). For the relationship of the drug concentrations tested to their determined IC 50 s in this cell line, see the data presented in Figure 5 . The adherent cells were collected at the indicated timepoints, and cell lysates were prepared as described in Materials and Methods. Except for GCV treatment of the non-HSV-TK-expressing HCT-116 cells, Figure 4A shows that Bak levels increased 1.5-to 3-fold in all four drug-treated cultures during the course of the treatment. In contrast to the results in Figures 3 and 4 for GCV, Bcl-X L levels decreased in response to CPT, UCN-01, or sodium butyrate treatments of HCT-116 cells (Fig 4B) . Taxol treatment resulted in increased levels of Bcl-X L , whereas again, GCV alone in these non-HSV-TK-expressing cells had little effect. Consistent with aspects of previous reports, 19 -24 increasing levels of Bak and down-regulation of Bcl-X L are part of the apoptotic mechanism of butyrate, CPT, and UCN-01 in these cells. This is in contrast to the effects of Taxol or GCV in HSV-TKexpressing cells, which resulted in increased levels of both proteins.
Cell viability of two-drug combinations of GCV plus another drug
In an effort to correlate the observed changes in the protein levels of Bak and Bcl-X L with drug dose and rate of apoptosis induction, a series of two-drug cell viability assays using MTT were done with GCV plus one of the other four drugs in the HCT-116.TK cells. One of the goals of these two-drug assays was to identify drug combinations that increased both the cell killing rate and amount of apoptosis in HSV-TK-expressing cells. Butyrate, CPT, Taxol, and UCN-01 induced apoptosis at equitoxic doses near their respective IC 50 s within 2 days of treatment. However, GCV required at least 4 days treatment time before significant cell killing was observed. Therefore, to meet our goal of increased cell killing, a timepoint of 2 days of drug treatment was used for these two-drug assays. An IC 50 of 0.1 M for GCV after 4 days of treatment in this cell line was established previously. 27 As presented in Figure 5 , HCT-116.TK cells were exposed to one of four doses of either butyrate, CPT, Taxol, or UCN-01 alone or in combination with three doses of GCV. For each graph, the x axis represents the non-GCV drug tested, and the first bar of each set represents the effect on cell viability of each drug alone (no GCV). Subsequent bars in each set represent increasing concentrations of GCV, and the 0 concentration drug set in each graph represents the effect of GCV alone. For each of the four combinations tested, a unique result was obtained. UCN-01 plus GCV resulted in increased cell killing at all concentrations tested (Fig 5A) . For example, UCN-01 at 0.25 M and GCV at 1 M resulted in 24% and 8% reductions in cell viability when tested alone, and when tested together resulted in 48% inhibition. For butyrate plus GCV, the results were mixed. At the lower butyrate and GCV concentrations tested, there was a slight increase in cell killing (Fig 5B) . At higher butyrate and GCV concentrations, cell viabilities appeared to be dependent only upon butyrate concentrations. For CPT, the addition of increasing concentrations of GCV led to increased cell viability relative to either drug alone (Fig 5C) . This latter effect was even more pronounced for Taxol plus GCV (Fig 5D) . Taxol alone was a very potent inhibitor, but there was a pronounced protective effect on cell viability with increasing concentrations of GCV. Analogous results with the above two-drug combinations were also found with the HT-29.TK and SW620.TK cell lines (data not shown).
Effect on Bak and Bcl-X L levels and nuclear DAPI staining after two-drug combination treatments
Representative concentrations of each two-drug combination were added to HCT-116.TK cells for 12-48 hours, and adherent cells were evaluated for differences in protein levels of Bak and Bcl-X L . As shown in Figure  6 , UCN-01 and butyrate plus GCV resulted in increased levels of Bak and decreased levels of Bcl-X L , an effect similar to UCN-01 or butyrate tested alone. For CPT and Taxol plus GCV, there was an increase in both Bak and Bcl-X L protein levels. This result is consistent with GCV and Taxol tested alone; however, it is opposite of that observed for CPT alone.
To evaluate whether the two-drug combinations re- sulted in increased numbers of apoptotic cells, HCT-116.TK cells were grown on slides and treated with representative concentrations of each two-drug combination. After 48 hours, the adherent cells were stained with DAPI, and the results are shown in Figure 7 . The results for UCN-01 plus GCV were consistent with the cell viability data in that the two drugs together resulted in greater numbers of cells undergoing apoptosis than either drug alone. The number of apoptotic nuclei after treatment with butyrate plus GCV or CPT plus GCV did not differ greatly from either drug tested alone. The Taxol plus GCV combination resulted in a protective effect in which the number of apoptotic nuclei were similar to GCV alone rather than the near total morphological nuclear changes induced by Taxol alone.
Two-drug clonal dilution assays
Another series of two-drug assays were done; however, analysis in this case consisted of a modified clonal dilution assay that we have used routinely for HSV-1 TK bystander effect assays. In this assay, single-or two-drug doses were added to 70% confluent HCT-116.TK or SW620.TK cells for 24 hours, followed by wash out of the drugs and dilution of the cells in 1:10 to 1:10,000 ratios in fresh media. Surviving cell colonies were counted after 7 days. As shown in Figure 8 for both cell lines, the butyrate (1.4 mM) plus GCV combinations consistently resulted in increased tumor cell killing when compared with either drug tested alone. Consistent with the MTT assays, Taxol (8 nM) plus GCV combinations resulted in killing of both cell lines that appeared to be entirely dependent upon GCV alone. For the SW620.TK cells, UCN-01 (2.5 M) plus GCV (0.01 or 0.1 M) resulted in nearly a 1-log increase in cell killing compared with either drug tested alone. However, this effect was not observed with UCN-01 plus GCV in the HCT-116.TK cells, and, in addition, five times higher doses of UCN-01 than those used in the MTT assays were required to obtain significant cell killing. For CPT treatments, the effect of cell dilution significantly increased tumor cell killing when tested alone or in combination with GCV at CPT doses that were 15-100 times lower than those used in the MTT assays (data not shown). This effect of CPT is currently being evaluated in a separate study. 
DISCUSSION
The primary goal of these studies was to identify potential GCV/drug combinations that resulted in both increased rates and amounts of tumor cell killing. In addition, this two-drug approach could aid in delineating the cellular regulatory mechanisms of GCV by comparing its action with better-characterized drugs such as CPT or Taxol. Therefore, the effects of these drug combinations on the protein levels of two Bcl-2 family members were determined: pro-apoptotic Bak and antiapoptotic Bcl-X L . In relation to the cell-killing rate of GCV, we had determined previously that GCV tested alone requires at least 4 days of treatment to determine an IC 50 dose profile in HSV-TK-expressing colon tumor cells. 27 Therefore, to identify drug combinations that increased the rate of cell death, cell viabilities were determined after only 2 days for each two-drug treatment. Even with drug combinations that were weakly effective, as in some of the butyrate/GCV concentrations, the rate of tumor cell killing was increased relative to GCV alone.
Combinations of UCN-01 and GCV proved to be most effective, resulting in increased tumor cell killing (Fig 5) , increased protein levels of Bak, decreased Bcl-X L levels (Fig 6) , and increased numbers of DAPIstained apoptotic nuclei (Fig 7) . Although not presented, we have seen similar effects of UCN-01 and GCV in five other HSV-TK-expressing colon tumor lines. The effect of UCN-01 on increasing Bak and decreasing Bcl-X L levels had not been reported previously, and we have observed similar increased cell killing by UCN-01/GCV combinations in three other HSV-TKexpressing colon cell lines (data not shown). UCN-01 has been shown to block cells at G 1 phase, 38 and when used in combination with another treatment, has also been shown to abrogate the S-phase block of CPT 39 and the G 2 block caused by ␥-irradiation or cisplatin. 40, 41 Our finding that UCN-01 increases cell killing when tested in combination with GCV is consistent with the ability of UCN-01 to abrogate cell cycle arrest. Thus, the baseline dose-response experiments presented for the two-drug combinations in Figure 5 can now be followed up with an evaluation of the effects of these combinations on cell cycle inhibition and cell cycle regulatory proteins. It was also apparent that UCN-01 was less effective in HCT-116.TK cells than SW620.TK cells in the clonal dilution assays in which drugs were removed after 24 hours. The basis for this difference is not known; it could merely reflect a poor half-life of UCN-01 in the HCT-116.TK cells. A more interesting possibility is that because UCN-01 is a protein kinase C class inhibitor, this may reflect different signal transduction pathway effects in the two cell lines; also interesting is the role of gap junctions in GCV metabolite transfer, which requires the cell-to-cell contact lost by the cell dilutions.
Butyrate plus GCV yielded mixed results in the MTT assay, with minimal increases in tumor cell killing; however, in the dilution assays, the two-drug combination was more effective than either drug alone. Also, GCV plus butyrate resulted in increased numbers of DAPI-stained apoptotic nuclei, increased Bak levels, and decreased Bcl-X L levels. The modulatory effect of butyrate on Bak or Bcl-X L levels has been reported previously. 20 -22,24,42 Butyrate has also been reported to act synergistically with ionizing radiation in human fibroblasts. 20 Because GCV incorporation into DNA and its subsequent damaging effect may be analogous to that caused by ionizing radiation, this may explain the minor potentiation of cell killing by butyrate in combination with HSV-TK/GCV.
In contrast to the results obtained with UCN-01 and butyrate, the CPT/GCV and Taxol/GCV combinations 5 cells/well) in 1 mL of media. The next day, the following drugs, singly or in combination with GCV, were added to each cell line in triplicate. GCV, 0.01 or 0.1 M; butyrate, 1.4 mM; Taxol, 8 nM; UCN-01, 2.5 M. After 24 hours, media were removed from each well and cells were sequentially diluted from 1/10 to 1/10,000 in 1 mL of fresh media as described in Materials and Methods. After 7 days, surviving cell colonies were fixed in 100% methanol, stained with 0.1% methylene blue, and counted. The first black bar in each GCV data set represents the no drug control for all tested drugs; the adjacent gray and light gray bars represent 0.01 or 0.1 M GCV tested alone. For each subsequent drug listed on the x axis, the first bar represents that drug tested alone; the adjacent bars are in combination with GCV. resulted in increased cell viabilities (Fig 5) , increased Bak and Bcl-X L levels (Fig 6) , and decreased numbers of apoptotic nuclei (Fig 7) . In these drug combinations, the cellular factors responding to GCV appear to predominate, especially as CPT tested alone led to increased Bak and decreased Bcl-X L levels (Fig 4) with corresponding increases in apoptosis. Bcl-X L has been shown to block the cell death signals induced by CPT treatment in lymphoid cells, and this blockage was independent of topoisomerase I inhibition and CPT-induced inhibition of DNA synthesis. 43 In the CPT/GCV-treated colon tumor cells, it is possible that the increase in Bcl-X L protein levels caused by GCV may be blocking the CPT-induced cell death signals. This result is in contrast to a study done in ovarian tumor cells transduced with HSV-TK adenovirus in which coadministration of the CPT derivative topotecan was shown to increase GCV tumor cell killing. 44 The dilution assays with CPT and GCV were done to address these differences; however, the acute sensitivity of the diluted SW620.TK and HCT-116.TK cells treated with CPT or CPT/GCV precluded further analysis. Apparently, the cell-to-cell interactions that were part of the MTT assays, Bak/Bcl-X L blots, and DAPI staining assays, but missing in the dilution assays, play a modulatory role in CPT-induced apoptosis pathways.
Despite the sensitivity of the HCT-116 cells to Taxol, addition of GCV clearly protects the cells in the time frame of the experiments. It has been reported previously that Taxol was most effective at inducing apoptosis in gastric tumor cells in the early G 1 stage of the cell cycle.
45 Surprisingly, Taxol was largely ineffective at inducing apoptosis in these same gastric tumor cells when they were blocked at later phases of the cell cycle by stage-specific drugs, 45 even though Taxol is expected to cause phase arrest at the G 2 /M phase. 46 Because GCV has been reported to lead to cell cycle arrest between late G 1 and early G 2 phases, 11, 12, 17 our results with GCV and Taxol combinations are consistent with the reported ineffectiveness of Taxol in gastric cells arrested beyond the early G 1 phase. 45 Also, GCV plus another microtubule inhibitor, vinblastine, yielded effects that were similar to those observed with Taxol/GCV (data not shown). The observed increases in both Bak and Bcl-X L protein levels (Fig 4) after Taxol treatment of the colon cells are in contrast to two previous studies. 25, 47 In prostate cells, it was shown that levels of Bcl-X L protein and mRNA decreased in response to Taxol, whereas Bak levels did not change. 47 In ovarian tumor cells, it was reported that Taxol led to increased Bak levels, but had no effect on Bcl-X L protein levels. 25 Understanding how GCV protects against the potent cytotoxic effects of Taxol in these colon cell lines should aid in delineating the mechanistic pathways for each of the drugs.
It has been postulated that observed increases in Bcl-X L expression, decreases in Bak expression, or both events, are important in the inhibition of apoptosis during the progression of this colon carcinoma. 18 Minor increases in Bak protein levels after GCV treatment were observed in four of the five HSV-TKexpressing colon tumor cell lines tested. A similar persistent increase in Bak protein levels was detected in HCT-116 cells treated with either sodium butyrate, CPT, Taxol, or UCN-01 (Fig 4) . These results are consistent with the established role of Bak as the primary pro-apoptotic Bcl-2 family member in human colon tumor cells, 18, 24 and suggest that increased levels of Bak are a common feature of the apoptosis signaling pathways shared by all five drugs. An unexpected result was the increased expression of the anti-apoptotic protein Bcl-X L in four of the five GCV-treated HSV-TK-expressing cell lines and Taxol-treated cells. In contrast, the HCT-116 cells treated with butyrate, CPT, or UCN-01 showed a decrease in the protein levels of Bcl-X L (Fig 4) . In the two-drug studies, the effective GCV/UCN-01 and GCV/butyrate combinations resulted in increased Bak and decreased Bcl-X L protein levels that correlated with increased induction of apoptosis and an increase in the rate and extent of tumor cell killing. This is consistent with the upset in the balance between the levels of pro-apoptotic and anti-apoptotic Bcl-2 protein family members being a proposed mechanism for induction of apoptosis. 37 Also, our observation that GCV treatment alone or in combination with CPT and Taxol leads to increased levels of Bcl-X L may offer one explanation for the prolonged survival times of the colon tumor cells. It is conceivable that GCVinduced cell cycle inhibition in response to DNA damage or other signal, combined with the antiapoptotic increases in Bcl-X L , produces cytostatic cells that prolong cell viability before eventual apoptosis after 4 -5 days. However, these effects on Bak and Bcl-X L levels remain correlative, as highlighted by the SW480.TK cell lines that are not affected and the high sensitivity of the colon cells to Taxol. Despite this, monitoring the changes in Bak and Bcl-X L levels in response to GCV and two-drug combinations should prove useful as a positive diagnostic tool for identifying effective drug combinations in colon tumor lines. This approach is currently being evaluated in our other HSV-TK-expressing colon tumor cells, as well as in studies to determine the efficacy of combination gene therapies using HSV-TK and Bak genes with GCV and another apoptosis-inducing drug. Additional two-drug studies using isobologram analyses and determining the effects of order of drug addition are also being evaluated.
